Melanomas in patients from New Zealand's South Island are significantly more likely than those of North Islanders to carry a gene mutation that has implications for mutation-targeted drug therapies and for patient outcomes, new University of Otago-led research suggests.
The study, which is the first comprehensive genetic analysis of melanoma in New Zealand, sought to analyse mutation frequencies of 20 recurrently mutated genes in samples from 529 patients with metastatic melanoma.